Award
NIH Reporter #11300255
Preclinical efficacy of GPR56 antibody-drug conjugates and combination therapies for triple-negative breast cancer
Recipient
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Award Amount
$178,846.00
Ceiling
$178,846.00
Awarded
March 09, 2026
Identifier
11300255
Award for research on GPR56 antibody-drug conjugates and combination therapies targeting triple-negative breast cancer, led by Dr. Kendra S. Carmon at University of Texas Health Science Center Houston, with an award amount of approximately $178,846.
Description
The project involves generating GPR56-targeted antibody-drug conjugates and evaluating their efficacy alone and in combination with PARP inhibitors for the treatment of triple-negative breast cancer. The project aims to develop targeted therapies with minimal toxicity and evaluate their efficacy in preclinical models.